论文部分内容阅读
With the economic downturn,the R&D budget for drug development had been under a lot of scrunity.Every player is trying to make the most out of their investment.On the other hand,increased awareness on general public and regulatory authorities demand higher and higher quality of drug development work,especially safety profile of the product.Bridge Laboratories will share insights into the current status and trends of the China preclinical safety sector and how companies can leverage conducting work in Asia.Bridge is a preclinical CRO that provides US-level regulatory compliant drug development services globally and is among the leading and most established "western standard" CROs in China.The presentation will be based on an evaluation ofpreclinical CROs in China and Bridges experience in providing GLP toxicology services through our Beijing lab.